DNA graphic

Funding Opportunities

The Lupus Research Alliance seeks to fund biomedical research that will discover better diagnostics, improve medical treatments and advance translational and clinical research that will ultimately lead to a cure for lupus. Our grant funding opportunities provide distinct opportunities for researchers to test their most innovative hypothesis by applying cutting edge methodologies to further investigation in the lupus and autoimmune space.

Lupus Innovation Award (formerly known as the Novel Research Grant): up to $150,000/year total costs for up to 2 years.

Applications are due on January 15, 2020.

Provides support for pioneering, high-risk, high-reward approaches to major challenges in lupus research. Special emphasis is placed on lupus studies exploring fundamental mechanisms, novel targets and pathways, novel technologies, and interdisciplinary approaches. Both early career and established investigators new to lupus with highly innovative ideas are encouraged to apply. Early stage investigators are eligible for an additional third year of funding contingent upon successful completion of the original grant.

Please note that while the Lupus Innovation Award and the Lupus Mechanisms and Targets Award funding mechanisms follow the same review timeline, they have distinct objectives, application templates, and selection criteria. Applicants are urged to carefully review the individual grant program guidelines detailed in the RFA. The same research project may not be submitted for consideration to both grant mechanisms.  Such submissions will be triaged without review.

 Applicants are encouraged to consult with LRA scientific staff to discuss the responsiveness of their proposal to this program.

Click here for the Request for Applications.
Please send any scientific inquiries to:
Dr. Shayla Shorter, Scientific Program Manager at sshorter@lupusresearch.org;

All administrative inquiries should be sent to:
Diomaris Gonzalez, Director, Grant Programs at dgonzalez@lupusresearch.org.

Lupus Mechanisms and Targets Award (formerly known as the Target Identification in Lupus grant): up to $200,000/year total costs for up to three years. Supports highly meritorious research focused on the identification and/or investigation of molecular pathways or targets that will lead to new or improved therapies for patients with lupus.

Applications are due on January 15, 2020.

Please note that while the Lupus Innovation Award and the Lupus Mechanisms and Targets Award funding mechanisms follow the same review timeline, they have distinct objectives, application templates, and selection criteria. Applicants are urged to carefully review the individual grant program guidelines detailed in the RFA. The same research project may not be submitted for consideration to both grant mechanisms.  Such submissions will be triaged without review.

Applicants are encouraged to consult with LRA scientific staff to discuss the responsiveness of their proposal to this program.

Click here for the Request for Applications.

Please send any scientific inquiries to:
Dr. Shayla Shorter, Scientific Program Manager at sshorter@lupusresearch.org;

All administrative inquiries should be sent to:
Diomaris Gonzalez, Director, Grant Programs at dgonzalez@lupusresearch.org.

 

Distinguished Innovator Award: provides outstanding scientists with substantial support (up to $1 million over 4 years) to conduct highly innovative research into the fundamental causes of systemic lupus erythematosus and so provide new directions towards a cure.

We encourage applications from investigators in diverse disciplines.
Click here for the Request for Applications

Letters of Intent due: March 16, 2020

Please do not hesitate to reach out to us if you have any questions. Inquiries are best sent via email to:

Scientific: Shayla Shorter, PhD (sshorter@lupusresearch.org)

Administrative: Diomaris Gonzalez (dgonzalez@lupusresearch.org)

The LRA-Celgene Accelerator Awards provide up to $150,000 per year for up to two years. The awards aim to fund cutting-edge research projects that focus on understanding the underlying mechanism of disease, addressing lupus heterogeneity, and identifying novel biomarkers. The program’s objective is to stimulate lupus research innovation, accelerate investigation on human lupus rather than relevant model organisms, and realize synergies between academia and industry.

Examples of pertinent topics include, but are not limited to:

  • Mechanism of disease: Mining of bulk and single-cell transcriptomic and proteomic datasets derived from lupus patient blood and target tissues (e.g., skin, joint, kidney);
  • Target discovery and validation: Characterization of genetic drivers of lupus, such as but not limited to understanding gain-of-function or loss-of-function risk alleles, eQTLS, or mRNA splicing;
  • Biomarker identification: Identify or validate early biomarkers of clinical flares, remission or response to therapy;
  • Patient selection: Novel methods of identifying SLE patient subsets based on immunological and clinical heterogeneity;
  • Clinical endpoint derivation and harmonization: addressing the need for outcome measures for skin disease, lupus-specific arthritis measures, and other endpoints that would facilitate and accelerate the conduct of clinical trials in lupus and its complications.

Please send any scientific inquiries to Dr. Teodora Staeva, Chief Scientific Officer at tstaeva@lupusresearch.org; all administrative inquiries should be sent to Diomaris Gonzalez, Director, Grant Programs at dgonzalez@lupusresearch.org.

Currently, we are not accepting any applications for this grant mechanism. However, we encourage you to contact us if you are interested in receiving future requests for proposals.

Learn and connect with our community!